Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.

ABSTRACT: The combination of venetoclax with hypomethylating agents is currently the standard of care for elderly patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. Despite its favorable efficacy, clinical use is often associated with post-remission cytopenia, frequently necessitating treatment delays and dose modifications. This study aims to evaluate the efficacy and safety of shortened venetoclax treatment durations. A multicenter analysis was conducted involving 20 adult AML patients receiving venetoclax (7 or 14 days with 9 and 11 patients, respectively) combined with 5-azacitidine (5-7 days) between 2021 and 2024. The cohort included patients from four German academic centers all treated in first line. Outcome measures included bone marrow response, transfusion d

SUBMITTER: Fleischmann M 

PROVIDER: S-EPMC11868173 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature